Registered title, quoted from ClinicalTrials.gov
Sentinel Node Biopsy Vs Observation After Axillary PET
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT04072653, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: women only
Registered eligibility fields
invasive ductal carcinoma or DCIS proved by core needle biopsy
Inclusion criterion 3
patients is accessible for the following axillary surgery and pathological test(including sentinel lymph node biopsy and axillary lymph node dissection)
Inclusion criterion 6
invasive carcinoma proved by core needle biopsy
Inclusion criterion 9
negative preoperative axillary assessment(including body examination, ultrasound and axillary PET mSUV<0.27)
Inclusion criterion 11
positive preoperative axillary assessment (including body examination, ultrasound and PET mSUV≥0.27)
Exclusion criterion 11
pregnancy or breastfeeding
Exclusion criterion 4
pregnancy or breastfeeding
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04072653, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
stage 1:
- female
- ≥18 years old
- invasive ductal carcinoma or DCIS proved by core needle biopsy
- tumor size ≤ 5cm
- negative preoperative axillary assessment(including body examination, ultrasound and MR examination)
- patients is accessible for the following axillary surgery and pathological test(including sentinel lymph node biopsy and axillary lymph node dissection)
stage 2:
- female
- ≥18 years old
- invasive carcinoma proved by core needle biopsy
- has plan for breast conserving surgery and adjuvant radiation after surgery
- negative preoperative axillary assessment(including body examination, ultrasound and axillary PET mSUV<0.27)
- patients is accessible for the follow up
Exclusion Criteria:
stage 1:
- distant metastases
- in the procedure of neoadjuvant therapy
- positive preoperative axillary assessment (including body examination, ultrasound and MR examination)
- pregnancy or breastfeeding
- axillary biopsy or axillary surgery before LymphPET
- suffer from diabetes mellitus and without well control of bloodglucose
- previous malignancy
- allergic to tracer of LymphPET
stage 2:
- distant metastases
- in the procedure of neoadjuvant therapy
- positive preoperative axillary assessment (including body examination, ultrasound and PET mSUV≥0.27)
- pregnancy or breastfeeding
- axillary biopsy or axillary surgery before LymphPET
- suffer from diabetes mellitus and without well control of bloodglucose
- previous malignancy
- allergic to tracer of LymphPET
Quoted from ClinicalTrials.gov, NCT04072653, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT04072653, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.